MB

Mehak Bansal

Active Director Additional Director DIN 11536962
DIN 11536962 First appointment Feb 2026
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Mehak Bansal

Data last updated:

Mehak Bansal is an Additional Director at Agi Clio Healthcare Private Limited (since 2026).

DIN 11536962
Primary Designation Additional Director
First Appointment 20 Feb 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Agi Clio Healthcare Private Limited U86100PB2024PTC061318
Additional Director20 Feb 2026Active

Directorship timeline

Open interactive timeline →
Agi Clio Healthcare Private Limited
Premium access

Shareholding and investment profile for Mehak Bansal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mehak Bansal

Mehak Bansal currently holds 1 directorship: Agi Clio Healthcare Private Limited (Additional Director, since 20 Feb 2026).

Mehak Bansal was first appointed on 20 Feb 2026 as Additional Director at Agi Clio Healthcare Private Limited.

The current boards of Mehak Bansal's companies include Gurpreet Singh Kochar (Agi Clio Healthcare Private Limited), Jasmeet Singh Dhingra (Agi Clio Healthcare Private Limited), Nirmaljeet Singh Malhi (Agi Clio Healthcare Private Limited), Rajiv Grover (Agi Clio Healthcare Private Limited), Venus (Agi Clio Healthcare Private Limited), Vikas Deep Bansal (Agi Clio Healthcare Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available